STOCK TITAN

Veradigm Inc - MDRX STOCK NEWS

Welcome to our dedicated news page for Veradigm (Ticker: MDRX), a resource for investors and traders seeking the latest updates and insights on Veradigm.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Veradigm's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Veradigm's position in the market.

Rhea-AI Summary
Veradigm, a healthcare data and technology solutions provider, announced that Practice Fusion has been ranked first for Ambulatory EHR PM Family Practice and Ambulatory EHR PM Primary Care General Practice by Black Book. Practice Fusion, a cloud-based EHR system, supports over 31,000 clinicians and 5 million patients monthly, offering comprehensive features to streamline administrative tasks and improve patient care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.84%
Tags
none
-
Rhea-AI Summary
Veradigm Inc. (OTCMKTS: MDRX) executives to participate in fireside chat at KeyBanc Capital Markets Forum. Webcast available on company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.6%
Tags
conferences
-
Rhea-AI Summary
Veradigm Inc. (MDRX) reaffirms fiscal 2023 estimated ranges for GAAP Revenue, Adjusted EBITDA, and Non-GAAP diluted earnings per share. Additionally, they introduce initial financial guidance for Fiscal 2024, expecting revenue between $620 million and $635 million, Adjusted EBITDA between $104 million and $113 million, and Net Cash of approximately $140 million post-acquisition of ScienceIO. The company emphasizes investment in all lines of business to drive growth and margin expansion, leveraging their strong presence in healthcare intelligence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.03%
Tags
Rhea-AI Summary
Veradigm Inc. (MDRX) has completed the acquisition of ScienceIO, a leading AI platform provider for healthcare. Dr. Yin Ho, Veradigm's Interim CEO, highlighted the potential to deliver insights faster using ScienceIO's large language model (LLM) combined with Veradigm's dataset.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
-
Rhea-AI Summary
Veradigm Inc. (MDRX) executives to participate in fireside chat and investor Q&A at Barclays Global Healthcare Conference on March 13, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.4%
Tags
conferences
-
News
Rhea-AI Summary
Sprinklr Inc. (CXM) will replace Veradigm Inc. (MDRX) in the S&P SmallCap 600 due to Veradigm's suspension from the Nasdaq Stock Market for non-compliance. The change will be effective on March 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
none
Rhea-AI Summary
Veradigm Inc. (MDRX) announces Dr. Yin Ho and Lee Westerfield to present at TD Cowen Annual Health Care Conference on March 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.39%
Tags
conferences
-
Rhea-AI Summary
Veradigm Inc. (NASDAQ: MDRX) received a notice from Nasdaq indicating delisting due to noncompliance with listing rules. The company is working to file overdue reports and regain compliance, but trading will be suspended from February 29, 2024. Veradigm does not plan to request a review of the decision. The stock is expected to be quoted on an over-the-counter market. The delisting also affects the company's outstanding convertible notes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.39%
Tags
none
-
News
Rhea-AI Summary
Veradigm Inc. (NASDAQ: MDRX) announced the acquisition of ScienceIO, a leading healthcare AI platform provider, to build advanced language models for healthcare. The acquisition aims to leverage ScienceIO's AI platform on Veradigm's extensive data set to enhance customer experience, improve outcomes, and lower costs across the healthcare ecosystem. Veradigm reaffirmed its 2023 financial information and positions itself for future growth as a higher-margin technology and data products company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.54%
Tags
Rhea-AI Summary
Veradigm Inc. (NASDAQ: MDRX) expects to receive a delisting notice from Nasdaq due to delayed financial filings, plans to restore compliance, and adopts a limited duration stockholder rights plan. The plan aims to protect stockholders' interests and prevent creeping acquisitions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.54%
Tags
none
Veradigm Inc

OTC:MDRX

MDRX Rankings

MDRX Stock Data

828.83M
69.64M
1.32%
128.9%
Computer Systems Design Services
Professional, Scientific, and Technical Services
Link
US
Chicago

About MDRX

allscripts (nasdaq: mdrx) is a leader in healthcare information technology solutions that advance clinical, financial and operational results. our innovative solutions connect people, places and data across an open, connected community of health™. connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. to learn more, visit www.allscripts.com, twitter, youtube and blog.allscripts.com.